Analysis of MTMR1 expression and correlation with muscle pathological features in juvenile/adult onset myotonic dystrophy type 1 (DM1) and in myotonic dystrophy type 2 (DM2)

Experimental and Molecular Pathology

Volumn 89, Issue 2, 2010, Pages 158-168

  Santoro, Massimo ^a,b   Modoni, Anna ^a   Masciullo, Marcella ^a   Gidaro, Teresa ^a   Broccolini, Aldobrando ^a,b   Ricci, Enzo ^a,b   Tonali, Pietro Attilio ^a,b   Silvestri, Gabriella ^a,b  

^a CATHOLIC UNIVERSITY   (Italy)

^b IRCCS FONDAZIONE DON CARLO GNOCCHI   (Italy)

Author keywords

MTMR1; Myotonic dystrophy; NCAM

Indexed keywords

BINDING PROTEIN; CUG BINDING PROTEIN 1; MUSCLEBLIND LIKE 1 PROTEIN; MYOSIN HEAVY CHAIN; MYOTUBULARIN RELATED 1 PROTEIN; NERVE CELL ADHESION MOLECULE; UNCLASSIFIED DRUG; VIMENTIN; CELF1 PROTEIN, HUMAN; MBNL1 PROTEIN, HUMAN; MTMR1 PROTEIN, HUMAN; NON RECEPTOR PROTEIN TYROSINE PHOSPHATASE; RNA BINDING PROTEIN;

ADULT; AGED; ALTERNATIVE RNA SPLICING; ARTICLE; CELL MATURATION; CELLULAR DISTRIBUTION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE CLASSIFICATION; FEMALE; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MUSCLE BIOPSY; MUSCLE CELL; MUSCLE FIBER CULTURE; MYOTONIC DYSTROPHY; PROTEIN LOCALIZATION; STEADY STATE; CASE CONTROL STUDY; CELL CULTURE; COMPARATIVE STUDY; GENETICS; METABOLISM; MIDDLE AGED; MUSCLE; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADULT; ALTERNATIVE SPLICING; CASE-CONTROL STUDIES; CELLS, CULTURED; FEMALE; HUMANS; MALE; MIDDLE AGED; MUSCLES; MYOTONIC DYSTROPHY; PROTEIN TYROSINE PHOSPHATASES, NON-RECEPTOR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA-BINDING PROTEINS;

EID: 77956440935     PISSN: 00144800     EISSN: 10960945     Source Type: Journal    
DOI: 10.1016/j.yexmp.2010.05.007     Document Type: Article

References (55)

1. Amack J.D., Mahadevan M.S. Myogenic defects in myotonic dystrophy. Dev. Biol. 2004, 265:294-301.
2. Anvret M., Ahlberg G., Grandell U., Hedberg B., Johnson K., Edström L. Larger expansions of the CTG repeat in muscle compared to lymphocytes from patients with myotonic dystrophy. Hum. Mol. Genet. 1993, 2:1397-1400.
3. Askanas V., Engel W.K. Cultured normal and genetically abnormal human muscle. Handbook of Clinical Neurology 1992, 85-116. Elsevier Science Publisher, Amsterdam. L.P. Rowland, S. Di Mauro (Eds.).
4. Baldwin T.J., Fazeli M.S., Doherty P., Walsh F.S. Elucidation of the molecular actions of NCAM and structurally related cell adhesion molecules. J. Cell. Biochem. 1996, 61:502-513.
5. Bassez G., Chapoy E., Bastuji-Garin S., Radvanyi-Hoffman H., Authier F.J., Pellissier J.F., Eymard B., Gherardi R.K. Type 2 myotonic dystrophy can be predicted by the combination of type 2 muscle fiber central nucleation and scattered atrophy. J. Neuropathol. Exp. Neurol. 2008, 67:319-325.
6. Bonifazi E., Vallo L., Giardina E., Botta A., Novelli G. A long PCR-based molecular protocol for detecting normal and expanded ZNF9 alleles in myotonic dystrophy type 2. Diagn. Mol. Pathol. 2004, 13:164-166.
7. Botta A., Vallo L., Rinaldi F., Bonifazi E., Amati F., Biancolella M., Gambardella S., Mancinelli E., Angelini C., Meola G., Novelli G. Gene expression analysis in myotonic dystrophy: indications for a common molecular pathogenic pathway in DM1 and DM2. Gene Expr. 2007, 13:339-351.
8. Broccolini A., Gidaro T., Morosetti R., Gliubizzi C., Servidei T., Pescatori M., Tonali P.A., Ricci E., Mirabella M. Neprilysin participates in skeletal muscle regeneration and is accumulated in abnormal muscle fibres of inclusion body miositi. J. Neurochem. 2006, 96:777-789.
9. Brook J.D., McCurrach M.E., Harley H.G., Buckler A.J., Church D., Aburatani H., Hunter K., Stanton V.P., Thirion J.P., Hudson T., Sohna R., Zemelmana B., Snellb R.G., Rundleb S.A., Crowb S., Daviesb J., Shelbourneb P., Buxtonb J., Jonesb C., Juvonenb V., Johnsonb K., Harperb P.S., Shawb J., Housmana D.E. Molecular basis of myotonic dystrophy: expansion of a trinucleotide (CTG) repeat at the 3' end of a transcript encoding a protein kinase family member. Cell 1992, 68:799-808. Erratum in: Cell 69, 385.
10. Buj-Bello A., Furling D., Tronchère H., Laporte J., Lerouge T., Butler-Browne G.S., Mandel J.L. Muscle-specific alternative splicing of myotubularin-related 1 gene is impaired in DM1 muscle cells. Hum. Mol. Genet. 2002, 11:2297-2307.
11. Cardani R., Mancinelli E., Sansone V., Rotondo G., Meola G. Biomolecular identification of (CCTG)n mutation in myotonic dystrophy type 2 (DM2) by FISH on muscle biopsy. Eur. J. Histochem. 2004, 48:437-442.
12. Cho D.H., Tapscott S.J. Myotonic dystrophy: emerging mechanisms for DM1 and DM2. Biochim. Biophys. Acta 2007, 1772:195-204.
13. Dansithong W., Paul S., Comai L., Reddy S. MBNL1 is the primary determinant of focus formation and aberrant insulin receptor splicing in DM1. J. Biol. Chem. 2005, 280:5773-5780.
14. Davis B.M., McCurrach M.E., Taneja K.L., Singer R.H., Housman D.E. Expansion of a CUG trinucleotide repeat in the 3' untranslated region of myotonic dystrophy protein kinase transcripts results in nuclear retention of transcripts. Proc. Natl. Acad. Sci. U. S. A. 1997, 94:7388-7393.
15. Day J.W., Ranum L.P. Genetics and molecular pathogenesis of the myotonic dystrophies. Curr. Neurol. Neurosci. Rep. 2005, 5:55-59.
16. Day J.W., Ricker K., Jacobsen J.F., Rasmussen L.J., Dick K.A., Kress W., Schneider C., Koch M.C., Beilman G.J., Harrison A.R., Dalton J.C., Ranum L.P. Myotonic dystrophy type 2: molecular, diagnostic and clinical spectrum. Neurology 2003, 60:657-664.
17. Dubowitz V., Sewry C.A. Muscle Biopsy: a Practical Approach 2007, Saunders, London. third ed.
18. Fardaei M., Larkin K., Brook J.D., Gamshere H.M. In vivo co-localisation of MBNL protein with DMPK expanded-repeat transcripts. Nucleic Acids Res. 2001, 29:2766-2771.
19. Gennarelli M., Novelli G., Andreasi Bassi F., Martorell L., Cornet M., Menegazzo E., Mostacciuolo M.L., Martinez J.M., Angelini C., Pizzuti A., Baiget M., Dallapiccola B. Prediction of myotonic dystrophy clinical severity based on the number of intragenic [CTG]n trinucleotide repeats. Am. J. Med. Genet. 1996, 65:342-347.
20. Harper P.S., Rudel R. Myotonic dystrophy. Myology 1994, 1192-1219. Mc Graw Hill, New York. second ed. A.G. Engel, C. Franzini-Armstrong (Eds.).
21. Ho T.H., Charlet-B N., Poulos M.G., Singh G., Swanson M.S., Cooper T.A. Muscleblind proteins regulate alternative splicing. EMBO J. 2004, 23:3103-3112.
22. Ho T.H., Bundman D., Armstrong D.L., Cooper T.A. Transgenic mice expressing CUG-BP1 reproduce splicing mis-regulation observed in myotonic dystrophy. Hum. Mol. Genet. 2005, 14:1539-1547.
23. Ho T.H., Savkur R.S., Poulos M.G., Mancini M.A., Swanson M.S., Cooper T.A. Colocalization of muscleblind with RNA foci is separable from mis-regulation of alternative splicing in myotonic dystrophy. J. Cell Sci. 2005, 118:2923-2933.
24. Junghans R.P. Dystrophia myotonia: why focus on foci?. Eur. J. Hum. Genet. 2009, 28:1-11.
25. Kanadia R.N., Johnstone K.A., Mankodi A., Lungu C., Thornton C.A., Esson D., Timmers A.M., Hauswirth W.W., Swanson M.S. A muscleblind knockout model for myotonic dystrophy. Science 2003, 302:1978-1980.
26. Kuyumcu-Martinez N.M., Wang G.S., Cooper T.A. Increased steady-state levels of CUG-BP1 in myotonic dystrophy 1 are due to PKC-mediated hyperphosphorylation. Mol. Cell 2007, 2:68-78.
27. Ladd A.N., Charlet N., Cooper T.A. The CELF family of RNA binding proteins is implicated in cell-specific and developmentally regulated alternative splicing. Mol. Cell. Biol. 2001, 21:1285-1296.
28. Laporte J., Biancalana V., Tanner S.M., Kress W., Schneider V., Wallgren-Pettersson C., Herger F., Buj-Bello A., Blondeau F., Liechti-Gallati S., Mandel J.L. MTM1 mutations in X-linked myotubular miopathy. Hum. Mutat. 2000, 15:393-409.
29. Laporte J., Blondeau F., Buj-Bello A., Mandel J.L. The myotubularin family: from genetic disease to phosphoinositide metabolism. Trends Genet. 2001, 17:221-228.
30. Laporte J., Bendez F., Bolino A., Mandel J.L. Myotubularins, a large disease-associated family of cooperating catalytically active and inactive phosphoinositides phosphatases. Hum. Mol. Genet. 2003, 12:285-292.
31. Lilienbaum A., Li Z., Butler-Browne G., Bolmont C., Grimaud J.A., Paulin D. Human desmin gene: utilization as a marker of human muscle differentiation. Cell. Mol. Biol. 1988, 34:663-672.
32. Lin X., Miller J.W., Mankodi A., Kanadia R.N., Yuan Y., Moxley R.T., Swanson M.S., Thornton C.A. Failure of MBNL1-dependent post-natal splicing transitions in myotonic dystrophy. Hum. Mol. Genet. 2006, 15:2087-2097.
33. Liquori C.L., Ricker K., Moseley M.L., Jacobsen J.F., Kress W., Naylor S.L., Day J.W., Ranum L.P. Myotonic dystrophy type 2 caused by a CCTG expansion in intron 1 of ZNF9. Science 2001, 293:864-867.
34. Mahadevan M., Tsilfidis C., Sabourin L., Shutler G., Amemiya C., Jansen G., Neville C., Narang M., Barceló J., O'Hoy K., Leblond S., Earle-Macdonald J., de Jong P., Wieringa B., Korneluk R.G. Myotonic dystrophy mutation: an unstable CTG repeat in the 3' untranslated region of the gene. Science 1992, 255:1253-1255.
35. Mankodi A., Urbinati C.R., Yuan Q.P., Moxley R.T., Sansone V., Krym M., Henderson D., Schalling M., Swanson M.S., Thornton C.A. Muscleblind localizes to nuclear foci of aberrant RNA in myotonic dystrophy types 1 and 2. Hum. Mol. Genet. 2001, 10:2165-2170.
36. Mankodi A., Takahashi M.P., Jiang H., Beck C.L., Bowers W.J., Moxley R.T., Cannon S.C., Thornton C.A. Expanded CUG repeats trigger aberrant splicing of ClC-1 chloride channel pre-mRNA and hyperexcitability of skeletal muscle in myotonic dystrophy. Mol. Cell 2002, 10:35-44.
37. Mankodi A., Teng-Umnuay P., Krym M., Henderson D., Swanson M., Thornton C.A. Ribonuclear inclusions in skeletal muscle in myotonic dystrophy types 1 and 2. Ann. Neurol. 2003, 54:760-768.
38. Mathieu J., Boivin H., Meunier D., Gaudreault M., Bégin P. Assessment of a disease-specific muscular impairment rating scale in myotonic dystrophy. Neurology 2001, 56:336-340.
39. Miller J.W., Urbinati C.R., Teng-Umnuay P., Stenberg M.G., Byrne B.J., Thornton C.A., Swanson M.S. Recruitment of human muscleblind proteins to (CUG)(n) expansions associated with myotonic dystrophy. EMBO J. 2000, 19:4439-4448.
40. Orengo J.P., Chambon P., Metzger D., Mosier D.R., Snipes G.J., Cooper T.A. Expanded CTG repeats within the DMPK 3' UTR causes severe skeletal muscle wasting in an inducible mouse model for myotonic dystrophy. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:2646-2651.
41. Osborne R.J., Thornton C. RNA-dominant diseases. Hum. Mol. Genet. 2006, 15:162-169.
42. Pascual M., Vicente M., Monferrer L., Artero R. The muscleblind family of proteins: an emerging class of regulators of developmentally programmed alternative splicing. Differentiation 2006, 74:65-80.
43. Philips A.V., Timchenko L.T., Cooper T.A. Disruption of splicing regulated by a CUG-binding protein in myotonic dystrophy. Science 1998, 280:737-741.
44. Pisani V., Panico M.B., Terracciano C., Bonifazi E., Meola G., Novelli G., Bernardi G., Angelini C., Massa R. Preferential central nucleation of type 2 myofibers is an invariable feature of myotonic dystrophy type 2. Muscle Nerve 2008, 38:1405-1411.
45. Ranum L.P., Cooper T.A. RNA-mediated neuromuscular disorders. Annu. Rev. Neurosci. 2006, 29:259-277.
46. Salehi L.B., Bonifazi E., Stasio E.D., Gennarelli M., Botta A., Vallo L., Iraci R., Massa R., Antonini G., Angelini C., Novelli G. Risk prediction for clinical phenotype in myotonic dystrophy type 1: data from 2650 patients. Genet. Test. 2007, 11:84-90.
47. Salisbury E., Sakai K., Schoser B., Huichalaf C., Schneider-Gold C., Nguyen H., Wang G.L., Albrecht J.H., Timchenko L.T. Ectopic expression of cyclin D3 corrects differentiation of DM1 myoblasts through activation of RNA CUG-binding protein, CUG-BP1. Exp. Cell Res. 2008, 314:2266-2278.
48. Savkur R.S., Philips A.V., Cooper T.A. Aberrant regulation of insulin receptor alternative splicing is associated with insulin resistance in myotonic dystrophy. Nat. Genet. 2001, 29:40-47.
49. Taneja K.L., McCurrach M., Schalling M., Housman D., Singer R.H. Foci of trinucleotide repeat transcripts in nuclei of myotonic dystrophy cells and tissues. J. Cell Biol. 1995, 128:995-1002.
50. Timchenko L.T., Miller J.W., Timchenko N.A., DeVore D.R., Datar K.V., Lin L., Roberts R., Caskey C.T., Swanson M.S. Identification of a (CUG)n triplet repeat RNA-binding protein and its expression in myotonic dystrophy. Nucleic Acids Res. 1996, 24:4407-4414.
51. Timchenko N.A., Cai Z.J., Welm A.L., Reddy S., Ashizawa T., Timchenko L.T. RNA CUG repeats sequester CUGBP1 and alter protein levels and activity of CUGBP1. J. Biol. Chem. 2001, 27:7820-7826.
52. Tokuyasu K.T., Maher P.A., Singe S.J. Distributions of vimentin and desmin in developing chick myotubes in vivo. I. Immunofluorescence study. J. Cell Biol. 1984, 98:1961-1972.
53. Tokuyasu K.T., Maher P.A., Singer S.J. Distributions of vimentin and desmin in developing chick myotubes in vivo. II. Immunoelectron microscopic study. J. Cell Biol. 1985, 100:1157-1166.
54. Vihola A., Bassez G., Meola G., Zhang S., Haapasalo H., Paetau A., Mancinelli E., Rouche A., Hogrel J.Y., Laforêt P., Maisonobe T., Pellissie J.F., Krahe R., Eymard B., Udd B. Histopathological differences of myotonic dystrophy type 1 (DM1) and PROMM/DM2. Neurology 2003, 60:1854-1857.
55. Winter A., Bornemann A. NCAM, vimentin and neonatal myosin heavy chain expression in human muscle diseases. Neuropathol. Appl. Neurobiol. 1999, 25:417-424.